glp-1 news today cardiovascular outcomes 2025 november Pipeline Update: - Prime Therapeutics Cardiovascular Risks after GLP-1 Discontinuation
Description
10.1002/ccr3.83 65 NohomovichB.ShahA.HughesN
[DOI] [PubMed] [Google Scholar] 115.Nauck M.A., Meier J.J., Cavender M.A., Abd El Aziz M., Drucker D.J
Dynamics and ecological reassembly of the human gut microbiome and the host metabolome in response to prolonged fasting

GLP-1R agonists appear to perform favorably compared with other approved pharmacological agents for pediatric obesity

Several RCTs including SAVORTIMI 53 (saxagliptin) [52], EXAMINE (alogliptin) [53], and TECOS (sitagliptin) [54] have shown that DPP4 inhibitors did not significantly reduce stroke risk [1]

The emerging story of GLP-1 agonists and migraines is part of a larger narrative about how metabolic drugs are revealing connections between body systems that were previously studied in isolation
